{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6", "Q2", 400693064, "RED+BLUE STRATEGIES", 194273, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2017, "second_quarter", "2017-07-10T14:04:59.903000-04:00", 60000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6/\", \"filing_uuid\": \"d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2017, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"60000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Melanie Nathanson\", \"dt_posted\": \"2017-07-10T14:04:59.903000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"601 13th Street NW\", \"registrant_address_2\": \"11th Floor North\", \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20005\", \"registrant\": {\"id\": 400693064, \"url\": \"https://lda.senate.gov/api/v1/registrants/400693064/\", \"house_registrant_id\": null, \"name\": \"RED+BLUE STRATEGIES\", \"description\": \"Health Care Consulting\", \"address_1\": \"975 F St NW\", \"address_2\": \"Suite 550\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20004\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"MELANIE NATHANSON\", \"contact_telephone\": \"+1 202-258-9381\", \"dt_updated\": \"2026-02-25T17:01:10.141217-05:00\"}, \"client\": {\"id\": 194273, \"url\": \"https://lda.senate.gov/api/v1/clients/194273/\", \"client_id\": 51, \"name\": \"PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)\", \"general_description\": \"PCMA represents pharmacy benefit managers, who administer the nation's covered Rx benefits\", \"client_government_entity\": false, \"client_self_select\": false, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": null, \"ppb_state_display\": null, \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2011-01-14\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \\n\\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \\n\\nS. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \\n\\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \\n\\nIssues related to the price of prescription medications in the United States.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54544, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MELANIE\", \"nickname\": null, \"middle_name\": \"JAN\", \"last_name\": \"NATHANSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 145382, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MEGAN\", \"nickname\": null, \"middle_name\": \"HAUCK\", \"last_name\": \"MARSHALL\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 11, \"name\": \"Executive Office of the President (EOP)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 18, \"name\": \"Office of Management & Budget (OMB)\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \\n\\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \\n\\nIssues related to the cost of prescription medications in the Medicare and Medicaid programs.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54544, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MELANIE\", \"nickname\": null, \"middle_name\": \"JAN\", \"last_name\": \"NATHANSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 145382, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MEGAN\", \"nickname\": null, \"middle_name\": \"HAUCK\", \"last_name\": \"MARSHALL\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 11, \"name\": \"Executive Office of the President (EOP)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 18, \"name\": \"Office of Management & Budget (OMB)\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \\n\\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \\n\\nS. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \\n\\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \\n\\nIssues related to the price of prescription medications in the United States.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 54544, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MELANIE\", \"nickname\": null, \"middle_name\": \"JAN\", \"last_name\": \"NATHANSON\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 145382, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"MEGAN\", \"nickname\": null, \"middle_name\": \"HAUCK\", \"last_name\": \"MARSHALL\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 11, \"name\": \"Executive Office of the President (EOP)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 18, \"name\": \"Office of Management & Budget (OMB)\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6"], "units": {}, "query_ms": 1.3269600458443165, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}